The SAKK 16/14 trial is the largest published trial of perioperative anti-PD-L1 therapy in addition to neoadjuvant chemotherapy in patients with resectable stage IIIA(N2) NSCLC; in this study, the addition of perioperative durvalumab to neoadjuvant chemotherapy with cisplatin and docetaxel resulted in a high 1-year event-free survival (EFS) rate of 73%, and mediastinal lymph node dissection was confirmed as one of the most important prognostic factors [22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.